State Street SPDR S&P Pharmaceuticals ETF
XPH
80 hedge funds and large institutions have $172M invested in State Street SPDR S&P Pharmaceuticals ETF in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 11 closing their positions.
2.57% more ownership
Funds ownership: 35.55% → 38.12% (+2.6%)
1% more funds holding
Funds holding: 79 → 80 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% less capital invested
Capital invested by funds: $172M → $172M (-$238K)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.16M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$3.25M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.1M |
| 4 |
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Tel Aviv,
Israel
|
+$2.98M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$8.32M |
| 2 |
TSS
Two Sigma Securities
New York
|
-$4.24M |
| 3 |
Citigroup
New York
|
-$2.72M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.78M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.65M |
XPH Hedge Fund Activity: Q2 2017 in Review
80 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2017, worth a combined $172M — down 0.14% from $172M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new XPH positions and 11 closed out — a net gain of 1 holder — while 23 added to existing stakes and 25 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $5.16M. The largest seller was UBS Group, cutting an estimated $8.32M.
- 80 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2017, up from 79 in Q1 2017.
- Funds reported $172M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2017, down 0.14% quarter-over-quarter.
- 12 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2017 and 11 closed out, a net change of +1 holder.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2017 was Goldman Sachs, an estimated $5.16M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2017 was UBS Group, an estimated $8.32M sold.
Based on aggregated 13F filings for Q2 2017.